ERBB2 and breast cancer: Particularly, auristatin F-based anti-HER-3 ADC, named EV20/MMAF, promoted durable tumor shrinkage in different preclinical models, including metastatic melanoma and breast cancer resistant to HER-2 inhibitors [19, 20].